German Corona Showcase. 25 Jun. 2020. 11:10am CET/5:10pm SGT

Brandenburg Gate, Berlin, Germany Photo by Ricardo Gomez Angel on Unsplash

Join Proteona at Bio Deutschland “Germany Corona Showcase”

Accelerate neutralizing antibody development with single cell analysis to protect vulnerable immunocompromised individuals

Dr Andreas Schmidt, CEO of Proteona, will present its neutralizing antibody development effort at the German Corona Showcase. His talk will take place on June 25, 2020 at 11:30am (CET)/5:10pm (SGT).

Dr Schmidt will discuss the recent progress at Proteona to develop neutralizing antibody targeting coronaviruses including SARS-CoV-2, the virus behind the COVID-19 pandemic. Proteona has formed an international alliance to leverage on its single cell analysis platform to accelerate the antibody discovery process. The alliance aims to develop neutralizing antibody therapy to protect individuals with compromised immune systems, such as those with blood cancer.

The event enables more than 50 companies to meet and discuss how to come up with new solutions to combat the coronavirus, ranging from diagnostics, therapies, to prevention.

The conference will take place virtually from the 23rd to the 25th of June. During the duration of the conference, partnering tools will be available for participants to arrange meetings and networking sessions.

Schedule a meeting

For media queries, please contact:

Dr Andreas Schmidt
Proteona Antibody Protection GmbH

About Proteona Antibody Protection GmbH

Proteona Antibody Protection GmbH is a biomedical company operating at the forefront of the fight against COVID-19 using single cell sequencing technology to discover neutralizing antibodies. Proteona’s vision is to accelerate treatment development for the most vulnerable, immunocompromised patients. Its parent company, Proteona, is already active in Singapore and Germany, where it provides single-cell multi-omics data for researchers, clinicians and pharma companies for drug discovery and for treatment optimization for blood cancer patients.